Physician profile
Gregory Everett Harris
NPI 1568789261
$4,577.81
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $1,383 · 2021: $1,129 · 2022: $605 · 2023: $905 · 2024: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.26 |
| Education | $115.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $473.40 | 2019-2023 | Tivdak, Adcetris |
| Astrazeneca Pharmaceuticals LP | $353.13 | 2020-2024 | Lynparza |
| Lexicon Pharmaceuticals, INC. | $298.70 | 2020 | |
| Incyte Corporation | $271.63 | 2020-2024 | Jakafi |
| Glaxosmithkline, LLC. | $248.48 | 2020-2021 | |
| Beigene USA, INC. | $247.38 | 2021 | |
| Pfizer INC. | $214.29 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $192.79 | 2019-2024 | |
| Puma Biotechnology, INC. | $182.56 | 2020-2024 | |
| Genentech USA, INC. | $170.38 | 2020-2022 | |
| Taiho Oncology, INC. | $169.38 | 2020-2021 | |
| Foundation Medicine, INC. | $168.91 | 2020-2023 | Foundationone Cdx |
| Janssen Biotech, INC. | $141.93 | 2019-2023 | Rybrevant |
| Daiichi Sankyo INC. | $124.99 | 2021 | |
| Mirati Therapeutics, INC. | $124.99 | 2023 | Krazati |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.